SecBot SecBot
DEFA14A ·Filed Nov 12, 2026

SLN

Silence Therapeutics plc
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 18h ago SEC0001193125-26-457070
Proxy solicitation materials
Actionable Insight • Neutral

The pending acquisition by Merck KGaA is the dominant corporate event; monitor shareholder vote and regulatory approvals for closing in Q1 2027. The Q3 results are largely backward-looking and overshadowed by the acquisition.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$19.80
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.15%
T+1 · $19.83
Vs SPY
+0.51%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $19.80entry
  2. T+1 · 4d ago +0.15%α +0.51% · $19.83
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics reported Q3 2026 results showing a reduced net loss of $12.4M ($0.08/share) versus $21.0M ($0.15/share) a year ago, driven by lower R&D and G&A expenses. The company also highlighted its definitive agreement to be acquired by Merck KGaA, expected to close in Q1 2027, and positive Phase 2 data for divesiran. The filing is a DEFA14A furnishing the earnings press release and solicitation materials related to the pending acquisition.

Key Financial Metrics

Vote
merger approval

Key Facts

  • Net loss for Q3 2026 was $12.4M ($0.08 per share), compared to $21.0M ($0.15 per share) in Q3 2025.
  • Cash and cash equivalents were $247.7M as of September 30, 2026, including $201.3M from an upsized public offering.
  • R&D expenses decreased to $9.3M from $20.5M year-over-year.
  • G&A expenses decreased to $4.9M from $5.8M year-over-year.
  • On October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, expected to close in Q1 2027.
  • Positive Phase 2 SANRECO trial results for divesiran in polycythemia vera reported on August 10, 2026.
  • Total outstanding shares were 186,609,073 as of September 30, 2026.

Financial Impact

Net loss improved by $8.5M year-over-year; cash position strengthened by $236.4M from year-end 2025.

net losscash and cash equivalentsR&D expensesG&A expenses

Risk Factors

  • Acquisition may not close due to failure to obtain regulatory or shareholder approvals, or other customary conditions.
  • Shareholder litigation could delay or derail the transaction.
  • Competing acquisition proposals could emerge.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-457070
Document: 0001193125-26-457070-index-headers.html0001193125-26-457070
Document: 0001193125-26-457070-index.html0001193125-26-457070
Document: 0001193125-26-457070.txt0001193125-26-457070

Track record

15 reports on SLN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026